Commercial-Ready Product with International Patent Filed
CQ1 (Mentabinol®) – As per CanaQuest’s September 17, 2019, press release, this game-changing discovery, Mentabinol®, protects consumers from acute & long-term negative psychiatric side effects of THC intake. This formulation utilizing Food-Grade Botanical Extract “BX” and extracted THC oil from the marijuana “MJ” plant addresses four major problems resulting from consuming THC for an extended time.
The application of Mentabinol® in pre-clinical trials at Western University have demonstrated:
- Reversal of depression-like and schizophrenia related symptom effects;
- Complete blockage of memory impairment;
- Complete blockage of hyperactive activity;
- Complete blockage of gene vulnerability.
Mentabinol® provides an alternative to Opioids.
The discovery was made by a research team led by Dr. Steven Laviolette, neuroscientist, at Western University, leading one of the two sponsored research programs that CanaQuest currently has with prominent Canadian universities.
.
.
PRODUCT FORMULATIONS
A critical mass of clinical evidence regarding the efficacy of medical cannabis is refuting political, scientific, and other skeptics, and opening minds hardened by decades of anti-cannabis propaganda. Our goal is to develop better alternative treatments to traditional pharmaceuticals for people struggling with a variety of health challenges.
CQ1 (Mentabinol®)
- Commercial Ready (THC + formula)
- Supports mental health: anxiety, depression, and schizophrenia.
CQ2 (Mentanine®)
- Commercial Ready (Omega 3 + formula)
- Supports mental health: Anxiety, depression, PTSD and addiction.
CQ3(Mentanine – pain®)
- Coming soon (Omega 3 + formula)
- To support endocannabinoid system health: Inflammation and pain.
CQ4(Menata…®)
- Coming soon
- To support mental health: Alzheimer’s